Callan Family Office LLC Purchases 421 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Callan Family Office LLC increased its stake in Eli Lilly and Company by 1.9% in the first quarter, owning a total of 22,926 shares valued at approximately $18.9 million.
• The company's earnings per share for the recent quarter were reported at $6.31, exceeding analysts' expectations, with a revenue of $15.56 billion.
• Eli Lilly recently announced a quarterly dividend of $1.50 per share, which will be paid on September 10th, reflecting an annualized yield of 0.9%.

Callan Family Office LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,926 shares of the company's stock after purchasing an additional 421 shares during the quarter. Eli Lilly and Company accounts for about 1.4% of Callan Family Office LLC's holdings, making the stock its 12th largest position. Callan Family Office LLC's holdings in Eli Lilly and Company were worth $18,935,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Knightsbridge Asset Management LLC raised its stake in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after purchasing an additional 15 shares during the period. LS Investment Advisors LLC increased its stake in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after acquiring an additional 40 shares during the last quarter. Prism Advisors Inc. bought a new position in Eli Lilly and Company in the 1st quarter worth about $207,000. CSM Advisors LLC increased its stake in Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after acquiring an additional 245 shares during the last quarter. Finally, Hemington Wealth Management increased its stake in Eli Lilly and Company by 14.4% in the 1st quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after acquiring an additional 124 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Leerink Partners restated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $964.88.

Eli Lilly and Company Trading Up 2.8%

LLY traded up $19.11 on Friday, hitting $702.04. 4,716,743 shares of the company were exchanged, compared to its average volume of 4,139,078. The firm has a fifty day simple moving average of $765.92 and a two-hundred day simple moving average of $795.40. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.53. The stock has a market capitalization of $664.45 billion, a PE ratio of 45.82, a price-to-earnings-growth ratio of 0.93 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the business posted $3.92 EPS. The business's revenue was up 37.6% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.9%. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.